-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11

Benzinga·05/14/2026 14:05:13
Listen to the news
Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $14 to $11.